Skip to main content
Clinical Trials/NCT04967183
NCT04967183
Recruiting
Not Applicable

Polyprev Study: Randomized, Multicenter, Controlled Trial Comparing Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs.

Fundacin Biomedica Galicia Sur1 site in 1 country3,788 target enrollmentJune 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Fundacin Biomedica Galicia Sur
Enrollment
3788
Locations
1
Primary Endpoint
Adverse effects
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Colorectal cancer (CRC) screening programs have been implemented to reduce the burden of the disease. When an advanced colonic lesions is detected, it is recommended to perform endoscopic surveillance with different intervals between explorations. Although the reduction in CRC incidence, endoscopic surveillance is producing a considerable increase in the number of colonoscopies. However, participation in CRC screening programs based on the fecal immunochemical test (FIT) could be a non inferior alternative to endoscopic surveillance.

Based on this hypothesis, the research group have designed a randomized clinical trial within the population CRC screening programs to compare FIT surveillance to endoscopic surveillance in patients with advanced lesions resected.

Detailed Description

Colorectal cancer (CRC) is one of the most common malignancies in western countries. CRC screening programs have been implemented in order to reduce the burden of the disease. Screening programs in Spain are based on the biennial detection of fecal hemoglobin with a fecal immunochemical test (FIT) and a diagnostic colonoscopy if positive. The detection of at least one advanced adenoma or serrated lesion defines a high risk situation for metachronous CRC. This group of patients is recommended to perform endoscopic surveillance with different intervals between explorations. Endoscopic surveillance reduces mortality only 1.7% and increases the number of colonoscopies by 62% with an additional cost of € 68,000 for an increase of 0.9 years of life. Moreover, colonoscopy is a procedure associated with potentially serious side effects. A recently British study shows that with a cut-off of 10 µg/g, FIT has a higher sensitivity and specificity for CRC with a significant cost reduction compared to colonoscopy surveillance. Additionally, most of the population prefers non-invasive faecal tests rather than colonoscopy. Based on this evidence, the research group have designed a multicenter, randomized clinical trial to compare the 10 year CRC incidence after resection of advanced colonic lesions detected within CRC screening programs between endoscopic surveillance and participation in CRC screening programs based on FIT. Apart from this purpose, the investigators will also assess the values and preferences regarding surveillance and risk of CRC. Further, the research group will evaluate the relationship between Mediterranean diet and physical activity with the detection of advanced adenomas and CRC.

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
June 2035
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundacin Biomedica Galicia Sur
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Individuals aged 50 to 65 years.
  • Individuals with at least one advanced adenoma (tubulovillous or villous histology, high grade dysplasia or ≥ 10mm), and / or at least three non-advanced adenomas detected and resected completely within the population-based CRC screening program.

Exclusion Criteria

  • Personal history of CRC.
  • Colonic lesion ≥10mm resected without histological diagnosis.
  • More than 10 adenomas in baseline colonoscopy.
  • Serrated polyposis syndrome.
  • Two or more first-degree relatives with CRC.
  • Hereditary predisposition to CRC.
  • Relevant comorbidity with life expectancy inferior to 5 years.
  • Colonoscopy with incomplete mucosal examination.
  • Incomplete resection of baseline lesions.
  • Non-acceptance after reading the informed consent.

Outcomes

Primary Outcomes

Adverse effects

Time Frame: 10 years

Adverse effects associated with surveillance are defined as complications that require hospitalization. Those related to the surgical treatment of benign colonic lesions will be included as adverse effects.

Mortality

Time Frame: 10 years

The deaths and their cause will be collected: associated with CRC, associated with adverse effects of screening or unrelated.

Rate of advanced colonic lesions

Time Frame: 10 years

Advanced colonic lesions will be defined as advanced adenomas (at least 10mm, hairy histology or high grade dysplasia) or advanced serrated lesions (at least 10mm or with dysplasia).

Frequency of participation in the surveillance strategy

Time Frame: 10 years

According to the methodology of the information systems of the screening programs, three categories will be defined: non-participation, irregular participation, regular participation.

Rate of invasive CRC

Time Frame: 10 years

It is the main outcome of the study. Invasive CRC is defined as colonic adenocarcinoma that invades the submucosa. Adenocarcinomas in situ and intramucosal carcinomas will not be considered as invasive CRC.

Rate of interval CRC

Time Frame: 10 years

Interval CRC is defined as the CRC detected between two organized surveillance (FIT or colonoscopy).

Secondary Outcomes

  • CRC, adenoma and advanced serrated lesions at three years(3 years)
  • Preferences of the subjects(2 years)
  • Physical activity(3 years)
  • Mediterranean lifestyle(3 years)

Study Sites (1)

Loading locations...

Similar Trials